Effects of cyclophosphamide administration on ovarian dysfunction in pediatric patients with connective tissue diseases: A systematic scoping review
article
OA: hybrid
CC0
Abstract
OBJECTIVE: This systematic scoping review assess the effect of cyclophosphamide (CY) administration during childhood on ovarian function in patients with juvenile-onset connective tissue diseases. METHODS: A MEDLINE database search was conducted using terms related to CY, juvenile-onset connective tissue diseases, and ovarian function. Studies were included if they met specific criteria. RESULTS: The search, conducted on 28 November 2023, yielded 3328 references. After a two-stage screening process, six observational studies on systemic lupus erythematosus patients were included. All studies had a high risk of confounding bias, as none adjusted for confounding variables. Two studies assessing clinical ovarian dysfunction found no clear difference between CY and non-CY groups. However, statistical differences were observed in hormonal profiles. Decreased ovarian reserve was more frequent in CY-exposed patients. Two studies showed significantly higher follicle-stimulating hormone (FSH) levels in the CY group, while one showed a trend towards higher FSH levels without statistical significance. CONCLUSION: This review suggested that CY use in childhood may not conclusively have clinically significant effects on ovarian function. Further investigation needed on CY's effect on hormonal levels, fertility, and pregnancy outcomes.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
References (17)
- doi:10.1002/1529-0131(199805)41:5<831::aid-art9>3.0.co;2-1 via openalex
- doi:10.1191/0961203306lu2291oa via openalex
- W165160785 via openalex
- doi:10.1136/annrheumdis-2020-216924 via openalex
- W2111387994 via openalex
- doi:10.7326/m18-0850 via openalex
- doi:10.1136/ard-2023-224762 via openalex
- W6606742050 via openalex
- doi:10.1177/0961203312468624 via openalex
- doi:10.1007/s00296-010-1389-2 via openalex
- doi:10.1191/0961203302lu219oa via openalex
- doi:10.3109/03009742.2014.908237 via openalex
- doi:10.1016/j.jclinepi.2012.09.016 via openalex
- doi:10.1177/0961203308094652 via openalex
- doi:10.1016/j.autrev.2022.103038 via openalex
- doi:10.4103/0366-6999.206346 via openalex
- doi:10.1191/0961203304lu2012oa via openalex
Source provenance
- openalex
- last seen: 2026-05-11T05:23:42.153812+00:00
License: CC0
· commercial use OK